2026 Q2 - tulosraportti
57 päivää sitten
‧1 t 1 min
1,73 USD/osake
Viimeisin osinko
0,56%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
Vuosittainen yhtiökokous 2026 4.5. | ||
2026 Q1 - tulosraportti 30.4. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 30.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
1 päivä sittenLilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison. https://investor.lilly.com/news-releases/news-release-details/lillys-zepbound-tirzepatide-10-mg-and-15-mg-was-associated-more- 1 päivä sittenLilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-172-mg-showed-greater-weight-loss
·23.9.Anyone know how far the lawsuits against Novo Nordisk, Eli Lilly etc. have progressed in relation to the NAION diagnosis (sudden vision loss)?Yes. The lawsuits are still in a relatively early phase, but they have become significantly more extensive over the past year. Brief status as of September 2026: The lawsuits against Novo Nordisk (Ozempic, Wegovy, etc.) and Eli Lilly (Mounjaro, Zepbound, etc.) have been consolidated into a US MDL (Multidistrict Litigation), no. 3163, in the federal court in Pennsylvania. The cases concern the allegation that the companies did not adequately warn about the risk of NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), a rare form of sudden and often permanent vision loss. There are now over 200 active cases in the federal MDL, and the number has increased continuously through 2026. Several sources indicate around 216 pending cases in September 2026. A parallel collection of cases is also running in New Jersey. The court has held a so-called Science Day, where the parties presented the scientific documentation for and against a connection between GLP-1 medicines and NAION. The cases are still mainly in the discovery phase (collection of internal documents, expert assessments, and evidence). No liability judgments have been handed down yet. According to available information, no bellwether trials (test cases) have been scheduled yet, nor any settlements. The scientific situation is central to the case It is important that the plaintiffs have not yet proven causation in court. The research shows mixed results: Some studies have found an elevated risk of NAION among users of semaglutide (Ozempic/Wegovy). Other analyses have been less definitive, and both Novo Nordisk and Eli Lilly argue that current evidence does not prove that the medicines cause NAION. Regulatory development The European Medicines Agency (EMA) assessed in 2025 that NAION should be listed as a very rare side effect of semaglutide products in Europe. The US FDA, on the other hand, has not yet required a specific NAION warning on US labels, but continues to investigate the safety signal. For Novo Nordisk investors, the relevant question is not only whether lawsuits have been filed, but whether the plaintiffs can document a clear causal connection. Historically, scientific documentation is often the decisive point in major pharmaceutical cases. At present, there is considerable legal activity, but no court has yet found Novo Nordisk or Eli Lilly liable for NAION. Source: Copilot
·7.9.I have posted a video about different philosophical angles in the weight loss debate, where I cover Novo and LLY, and explain why Zealand is an exciting prospect for an alternative angle: Novo Nordisk & Eli Lilly Have a New Problem https://youtu.be/O8UbY2EFsDY
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
57 päivää sitten
‧1 t 1 min
1,73 USD/osake
Viimeisin osinko
0,56%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 1 päivä sittenLilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison. https://investor.lilly.com/news-releases/news-release-details/lillys-zepbound-tirzepatide-10-mg-and-15-mg-was-associated-more
- 1 päivä sittenLilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-172-mg-showed-greater-weight-loss
- ·23.9.Anyone know how far the lawsuits against Novo Nordisk, Eli Lilly etc. have progressed in relation to the NAION diagnosis (sudden vision loss)?Yes. The lawsuits are still in a relatively early phase, but they have become significantly more extensive over the past year. Brief status as of September 2026: The lawsuits against Novo Nordisk (Ozempic, Wegovy, etc.) and Eli Lilly (Mounjaro, Zepbound, etc.) have been consolidated into a US MDL (Multidistrict Litigation), no. 3163, in the federal court in Pennsylvania. The cases concern the allegation that the companies did not adequately warn about the risk of NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), a rare form of sudden and often permanent vision loss. There are now over 200 active cases in the federal MDL, and the number has increased continuously through 2026. Several sources indicate around 216 pending cases in September 2026. A parallel collection of cases is also running in New Jersey. The court has held a so-called Science Day, where the parties presented the scientific documentation for and against a connection between GLP-1 medicines and NAION. The cases are still mainly in the discovery phase (collection of internal documents, expert assessments, and evidence). No liability judgments have been handed down yet. According to available information, no bellwether trials (test cases) have been scheduled yet, nor any settlements. The scientific situation is central to the case It is important that the plaintiffs have not yet proven causation in court. The research shows mixed results: Some studies have found an elevated risk of NAION among users of semaglutide (Ozempic/Wegovy). Other analyses have been less definitive, and both Novo Nordisk and Eli Lilly argue that current evidence does not prove that the medicines cause NAION. Regulatory development The European Medicines Agency (EMA) assessed in 2025 that NAION should be listed as a very rare side effect of semaglutide products in Europe. The US FDA, on the other hand, has not yet required a specific NAION warning on US labels, but continues to investigate the safety signal. For Novo Nordisk investors, the relevant question is not only whether lawsuits have been filed, but whether the plaintiffs can document a clear causal connection. Historically, scientific documentation is often the decisive point in major pharmaceutical cases. At present, there is considerable legal activity, but no court has yet found Novo Nordisk or Eli Lilly liable for NAION. Source: Copilot
- ·7.9.I have posted a video about different philosophical angles in the weight loss debate, where I cover Novo and LLY, and explain why Zealand is an exciting prospect for an alternative angle: Novo Nordisk & Eli Lilly Have a New Problem https://youtu.be/O8UbY2EFsDY
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
Vuosittainen yhtiökokous 2026 4.5. | ||
2026 Q1 - tulosraportti 30.4. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 30.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
57 päivää sitten
‧1 t 1 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
Vuosittainen yhtiökokous 2026 4.5. | ||
2026 Q1 - tulosraportti 30.4. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 30.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
1,73 USD/osake
Viimeisin osinko
0,56%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 1 päivä sittenLilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison. https://investor.lilly.com/news-releases/news-release-details/lillys-zepbound-tirzepatide-10-mg-and-15-mg-was-associated-more
- 1 päivä sittenLilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-172-mg-showed-greater-weight-loss
- ·23.9.Anyone know how far the lawsuits against Novo Nordisk, Eli Lilly etc. have progressed in relation to the NAION diagnosis (sudden vision loss)?Yes. The lawsuits are still in a relatively early phase, but they have become significantly more extensive over the past year. Brief status as of September 2026: The lawsuits against Novo Nordisk (Ozempic, Wegovy, etc.) and Eli Lilly (Mounjaro, Zepbound, etc.) have been consolidated into a US MDL (Multidistrict Litigation), no. 3163, in the federal court in Pennsylvania. The cases concern the allegation that the companies did not adequately warn about the risk of NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), a rare form of sudden and often permanent vision loss. There are now over 200 active cases in the federal MDL, and the number has increased continuously through 2026. Several sources indicate around 216 pending cases in September 2026. A parallel collection of cases is also running in New Jersey. The court has held a so-called Science Day, where the parties presented the scientific documentation for and against a connection between GLP-1 medicines and NAION. The cases are still mainly in the discovery phase (collection of internal documents, expert assessments, and evidence). No liability judgments have been handed down yet. According to available information, no bellwether trials (test cases) have been scheduled yet, nor any settlements. The scientific situation is central to the case It is important that the plaintiffs have not yet proven causation in court. The research shows mixed results: Some studies have found an elevated risk of NAION among users of semaglutide (Ozempic/Wegovy). Other analyses have been less definitive, and both Novo Nordisk and Eli Lilly argue that current evidence does not prove that the medicines cause NAION. Regulatory development The European Medicines Agency (EMA) assessed in 2025 that NAION should be listed as a very rare side effect of semaglutide products in Europe. The US FDA, on the other hand, has not yet required a specific NAION warning on US labels, but continues to investigate the safety signal. For Novo Nordisk investors, the relevant question is not only whether lawsuits have been filed, but whether the plaintiffs can document a clear causal connection. Historically, scientific documentation is often the decisive point in major pharmaceutical cases. At present, there is considerable legal activity, but no court has yet found Novo Nordisk or Eli Lilly liable for NAION. Source: Copilot
- ·7.9.I have posted a video about different philosophical angles in the weight loss debate, where I cover Novo and LLY, and explain why Zealand is an exciting prospect for an alternative angle: Novo Nordisk & Eli Lilly Have a New Problem https://youtu.be/O8UbY2EFsDY
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt